PE20091727A1 - Agentes terapeuticos antivirales - Google Patents
Agentes terapeuticos antiviralesInfo
- Publication number
- PE20091727A1 PE20091727A1 PE2009000334A PE2009000334A PE20091727A1 PE 20091727 A1 PE20091727 A1 PE 20091727A1 PE 2009000334 A PE2009000334 A PE 2009000334A PE 2009000334 A PE2009000334 A PE 2009000334A PE 20091727 A1 PE20091727 A1 PE 20091727A1
- Authority
- PE
- Peru
- Prior art keywords
- oxo
- alkyl
- therapeutic agents
- treatment
- antiviral therapeutic
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 abstract 1
- HMFHBZSHGGEWLO-AIHAYLRMSA-N alpha-D-ribose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-AIHAYLRMSA-N 0.000 abstract 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 abstract 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
- Y02T10/00—Road transport of goods or passengers
- Y02T10/10—Internal combustion engine [ICE] based vehicles
- Y02T10/30—Use of alternative fuels, e.g. biofuels
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3405308P | 2008-03-05 | 2008-03-05 | |
| US7937008P | 2008-07-09 | 2008-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091727A1 true PE20091727A1 (es) | 2009-12-04 |
Family
ID=41054287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000334A PE20091727A1 (es) | 2008-03-05 | 2009-03-05 | Agentes terapeuticos antivirales |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7994139B2 (enExample) |
| EP (1) | EP2265275A2 (enExample) |
| JP (1) | JP2011525171A (enExample) |
| KR (1) | KR20100137494A (enExample) |
| CN (1) | CN102834513A (enExample) |
| AR (1) | AR071745A1 (enExample) |
| AU (1) | AU2009221770A1 (enExample) |
| BR (1) | BRPI0910388A2 (enExample) |
| CA (1) | CA2717173A1 (enExample) |
| EA (1) | EA201070988A1 (enExample) |
| IL (1) | IL207826A0 (enExample) |
| MX (1) | MX2010009646A (enExample) |
| NZ (1) | NZ588179A (enExample) |
| PE (1) | PE20091727A1 (enExample) |
| TW (1) | TW200942243A (enExample) |
| WO (1) | WO2009111653A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598927A (en) * | 2007-01-12 | 2013-09-27 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| DK2155758T3 (da) * | 2007-05-10 | 2012-11-05 | Biocryst Pharm Inc | Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer |
| US20090247750A1 (en) * | 2008-03-28 | 2009-10-01 | Biocryst Pharmaceuticals, Inc. | Process for preparing nucleoside analogs |
| PL2280973T3 (pl) | 2008-04-23 | 2013-05-31 | Gilead Sciences Inc | Analogi karba-nukleozydowe do leczenia przeciwwirusowego |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| NZ599404A (en) | 2009-09-21 | 2014-02-28 | Gilead Sciences Inc | Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| EA025311B1 (ru) | 2010-07-19 | 2016-12-30 | Гайлид Сайэнсиз, Инк. | Способы получения диастереомерно чистых фосфорамидатных пролекарств |
| PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
| LT2898885T (lt) | 2010-10-15 | 2018-02-26 | Biocryst Pharmaceuticals, Inc. | Pirolopirimidino dariniai, skirti naudoti virusinių infekcijų gydymui |
| WO2013033093A1 (en) * | 2011-08-29 | 2013-03-07 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
| AR090699A1 (es) | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
| US8906929B2 (en) * | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2970297A1 (en) * | 2013-03-14 | 2016-01-20 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CN104946646B (zh) * | 2014-03-25 | 2020-03-31 | 中国医学科学院基础医学研究所 | 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用 |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| FI3265102T3 (fi) | 2015-03-06 | 2025-10-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten |
| DK3349758T3 (da) | 2015-09-16 | 2022-06-13 | Gilead Sciences Inc | Fremgangsmåder til behandling af arenaviridae-virusinfektioner |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| MX381542B (es) | 2016-03-06 | 2025-03-04 | Biocryst Pharm Inc | Métodos y composiciones para el tratamiento de la infección por el virus del zika. |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| CN115477679A (zh) | 2017-02-01 | 2022-12-16 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| EP4219513A1 (en) | 2017-05-01 | 2023-08-02 | Gilead Sciences, Inc. | Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
| CN111471056B (zh) * | 2019-01-23 | 2021-07-02 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| KR20220132608A (ko) | 2020-01-27 | 2022-09-30 | 길리애드 사이언시즈, 인코포레이티드 | SARS CoV-2 감염증을 치료하기 위한 방법 |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| JP7482250B2 (ja) | 2020-04-06 | 2024-05-13 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノ置換カルバヌクレオシド類似体の吸入製剤 |
| EP4157272B1 (en) | 2020-05-29 | 2025-07-02 | Gilead Sciences, Inc. | Remdesivir for the treatment of viral infections |
| IL299202A (en) | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| WO2022164941A1 (en) | 2021-01-26 | 2022-08-04 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
| AU2022256476B2 (en) | 2021-04-16 | 2025-06-05 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| AU2022291927A1 (en) | 2021-06-17 | 2024-01-04 | Atea Pharmaceuticals, Inc. | Advantageous anti-hcv combination therapy |
| CA3228162A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144032A0 (en) | 1999-01-13 | 2002-04-21 | Genentech Inc | Serine protease inhibitors |
| JP2002279640A (ja) | 2001-03-21 | 2002-09-27 | Ricoh Co Ltd | ウォブル検出回路とその装置 |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| WO2005021568A2 (en) * | 2003-08-27 | 2005-03-10 | Biota, Inc. | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| AU2005302448B2 (en) | 2004-10-29 | 2012-07-19 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
| HRP20070435A9 (en) | 2005-02-28 | 2008-09-30 | Genelabs Technologies | Tricyclic-nucleoside compounds for treating viral infections |
| WO2008005542A2 (en) * | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
| NZ598927A (en) | 2007-01-12 | 2013-09-27 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| DK2155758T3 (da) | 2007-05-10 | 2012-11-05 | Biocryst Pharm Inc | Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer |
-
2009
- 2009-03-04 TW TW098107018A patent/TW200942243A/zh unknown
- 2009-03-05 WO PCT/US2009/036213 patent/WO2009111653A2/en not_active Ceased
- 2009-03-05 PE PE2009000334A patent/PE20091727A1/es not_active Application Discontinuation
- 2009-03-05 BR BRPI0910388A patent/BRPI0910388A2/pt not_active IP Right Cessation
- 2009-03-05 JP JP2010549889A patent/JP2011525171A/ja not_active Withdrawn
- 2009-03-05 KR KR1020107022136A patent/KR20100137494A/ko not_active Withdrawn
- 2009-03-05 NZ NZ588179A patent/NZ588179A/xx not_active IP Right Cessation
- 2009-03-05 MX MX2010009646A patent/MX2010009646A/es not_active Application Discontinuation
- 2009-03-05 EP EP09716971A patent/EP2265275A2/en not_active Withdrawn
- 2009-03-05 AU AU2009221770A patent/AU2009221770A1/en not_active Abandoned
- 2009-03-05 US US12/398,866 patent/US7994139B2/en not_active Expired - Fee Related
- 2009-03-05 CN CN2009801168793A patent/CN102834513A/zh active Pending
- 2009-03-05 AR ARP090100788A patent/AR071745A1/es not_active Application Discontinuation
- 2009-03-05 CA CA2717173A patent/CA2717173A1/en not_active Abandoned
- 2009-03-05 EA EA201070988A patent/EA201070988A1/ru unknown
-
2010
- 2010-08-26 IL IL207826A patent/IL207826A0/en unknown
-
2011
- 2011-07-12 US US13/181,078 patent/US20120142617A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ588179A (en) | 2012-09-28 |
| CN102834513A (zh) | 2012-12-19 |
| IL207826A0 (en) | 2010-12-30 |
| US20090227524A1 (en) | 2009-09-10 |
| US7994139B2 (en) | 2011-08-09 |
| CA2717173A1 (en) | 2009-09-11 |
| MX2010009646A (es) | 2010-09-28 |
| US20120142617A1 (en) | 2012-06-07 |
| AU2009221770A1 (en) | 2009-09-11 |
| KR20100137494A (ko) | 2010-12-30 |
| WO2009111653A2 (en) | 2009-09-11 |
| EP2265275A2 (en) | 2010-12-29 |
| EA201070988A1 (ru) | 2011-12-30 |
| TW200942243A (en) | 2009-10-16 |
| AR071745A1 (es) | 2010-07-14 |
| WO2009111653A3 (en) | 2011-09-22 |
| JP2011525171A (ja) | 2011-09-15 |
| BRPI0910388A2 (pt) | 2019-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX348759B (es) | Metodos y composiciones para inhibicion de polimerasa. | |
| UY31476A1 (es) | Nucleosidos 2' , 4' -sustituidos como agentes antivirales | |
| PE20210668A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales | |
| PE20191552A1 (es) | Imidazo-quinolinas sustituidas como moduladores de receptores tipo dominio de oligomerizacion de fijacion a nucleotidos p3 (nlrp3) | |
| JP2018088924A5 (enExample) | ||
| PE20120257A1 (es) | Analogos carba-nucleosidicos para tratamiento antiviral | |
| GT200500221A (es) | Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan. | |
| CL2011001364A1 (es) | Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv). | |
| PE20151318A1 (es) | Analogos de 2'-cloro nucleosido para infeccion por vhc | |
| CL2013003053A1 (es) | Compuesto que comprende un oligonucleotido modificado que consiste en de 10 a 30 nucleósidos unidos y definidos por un grupo de secuencias específicas; composicion que comprende dicho compuesto; uso para tratar enfermedades relacionadas con el virus de la hepatitis b (vhb). | |
| UY33097A (es) | DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS | |
| PE20160658A1 (es) | Nucleosidos sustituidos, nucleotidos y analogos de los mismos | |
| CL2008000902A1 (es) | Ester isopropilo del acido (s)-2-{[(2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidro-2h-pirimidin-1-il)-4-fluoro-3-hidroxi-4-metil-tetrahidro-furan-2-il-metoxi]-fenoxi-fosforilamino}-propionico; proceso de preparacion, composicion farmaceutica y su uso para tratar hepatitis c, virus del west nile, virus de fiebre amarilla, virus del dengue, rinovirus, virus del polio. | |
| PE20050462A1 (es) | COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5) | |
| PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
| AR056850A1 (es) | MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA | |
| BR112012024923A2 (pt) | "fosforamidatos de nucleosídeo, composição, comprimido, e seus usos" | |
| EA201590943A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| PE20140522A1 (es) | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| PE20091458A1 (es) | Compuestos heterociclicos antiviricos | |
| EA201170915A1 (ru) | Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций | |
| CO6382185A2 (es) | Compuestos nucleosidos antivirales | |
| EA201592075A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| AR089650A1 (es) | Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales | |
| CO6321235A2 (es) | Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |